MarketPR
Merck (MRK) reported fiscal Q2 2026 total revenue of $16.6 billion, a 5.1% increase from a year earlier, while the company’s management shifted its strategic emphasis from the GARDASIL vaccine franchise to newer medicines.
This pivot occurred as the stock traded at 5.5 times sales, a premium to the S&P 500 multiple, prompting a reevaluation of the company’s core growth drivers.
During the fiscal Q2 2026 earnings call, executives highlighted the FDA approval of LIPFENDRA, described as the first and only oral PCSK9 inhibitor for reducing LDL cholesterol.
They also presented positive top-line results from a large Phase III program for sac-TMT, framing the company as more diversified.
Keep reading